Delisting riskPopularity #4,728
Mannatech (MTEX)
Direct seller of Ambrotose-centered nutritional supplements and personal-care products.
$8.00
After hours−0.14 (−1.78%)
At close$8.15(−0.06%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33 | 33 | 29 | 28 | 32 | 29 | 27 | 26 | 29 | 27 | 25 | 27 |
| Cost of revenue | 7 | 8 | 6 | 6 | 8 | 6 | 7 | 7 | 7 | 7 | 6 | 6 |
| Gross profit | 26 | 25 | 23 | 21 | 24 | 23 | 20 | 19 | 22 | 20 | 19 | 20 |
| 26 | 26 | 22 | 23 | 23 | 23 | 21 | 20 | 20 | 20 | 19 | 19 | |
| 20 | 28 | 11 | 11 | 10 | 10 | 10 | 11 | 9 | 10 | 9 | 19 | |
| Selling & marketing | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| General & administrative | 7 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Other expenses | 6 | −2 | 12 | 12 | 13 | 12 | 11 | 10 | 11 | 10 | 10 | 0 |
| Operating income | 0 | −1 | 1 | −1 | 1 | 1 | −1 | −1 | 2 | 0 | 0 | 1 |
| 0 | −1 | 1 | 1 | −2 | 2 | 0 | −3 | 1 | 0 | 1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 1 | −1 | −1 | 1 | −2 | 0 | 3 | −1 | 0 | −1 | 0 |
| Income before tax | 0 | −2 | 2 | 0 | −1 | 3 | −1 | −4 | 3 | 0 | 1 | 1 |
| Income tax expense | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 12 | 0 | 0 |
| Net income from continuing operations | 0 | −2 | 1 | −1 | 0 | 2 | −2 | −4 | 2 | −11 | 1 | 1 |
| Net income | 0 | −2 | 1 | −1 | 0 | 2 | −2 | −4 | 2 | −11 | 1 | 1 |
| EPS, basic | $0.01 | −$0.94 | $0.63 | −$0.33 | −$0.17 | $1.20 | −$0.80 | −$2.27 | $1.01 | −$5.94 | $0.49 | $0.53 |
| EPS, diluted | $0.01 | −$0.94 | $0.63 | −$0.33 | −$0.17 | $1.20 | −$0.80 | −$2.27 | $1.01 | −$5.94 | $0.49 | $0.53 |
| Weighted average shares, basic | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Weighted average shares, diluted | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | 1 | −1 | 2 | 0 | 0 | 3 | −1 | −3 | 3 | 1 | 1 | 2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| EBIT | 0 | −2 | 2 | 0 | −1 | 3 | −1 | −4 | 3 | 0 | 1 | 1 |
